Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results
August 11, 2022 16:05 ET
|
Larimar Therapeutics
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose...
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
July 28, 2022 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
June 28, 2022 08:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
June 02, 2022 08:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
May 19, 2022 08:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
May 12, 2022 07:00 ET
|
Larimar Therapeutics
- CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of...
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
March 25, 2022 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
February 14, 2022 16:01 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
November 15, 2021 07:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...